MSD is working with Seattle Genetics on two new oncology projects

, known as Merck in the U.S. and Canada, announced two new oncology collaborations with biotech company and oncologist Seattle Genetics.As part of the agreement, the two companies will jointly develop and commercialize Seattle's commercialized research antibody, the drug ladiratuzumab vedotin, which is currently in Phase II clinical trials of breast cancer and other solid tumors.The collaboration evaluates ADC as a monotherapy and works with MSD's PD-1 inhibitor Keytruda (Pim monoanti) to treat triple-negative breast cancer, hormone-positive breast cancer, and other solid tumors expressing LIV-1.Under the terms of the deal, Seattle will receive an advance of $600 million, while MSD will invest $1 billion in the company's 5 million shares at $200 a share. Most importantly, Seattle is also eligible for a milestone payment of up to $2.6 billion in progress related to the Radirato Single Antivedotin Clinical Program.In another agreement, Seattle also granted MSD exclusive license to sell Tucatinib, a small molecule tyrosine kinase inhibitor used to treat HER-2-positive cancers, in Asia, the Middle East and Latin America, and elsewhere. Outside the United States, Canada, and Europe.MSD will pay Seattle $125 million for the exclusive license, and Seattle will be eligible for a progress-related milestone of up to $65 million.“ Our partnership with Mercadon on Ladiratuzumab vedotin will enable us to accelerate and expand its development program for breast cancer and other solid tumors, including with Merck's Keytruda, while also enabling us to leverage our commercial operations in the United States and Europe," said Clay Siegall, President and CEO of Seattle Genetics.He added: "A strategic partnership with Tukysa will help us attract more patients globally and benefit from the strong commercial strength of one of the world's leading pharmaceutical companies." Roger M. Perlmutter, president ofMerck Research Laboratories, said, "These two strategic partnerships will enable us to further diversify Merck's broad portfolio and product line of oncology treatments and continue to expand and improve the lives of as many cancer patients as possible." ”（cyy123.com）